Replies to post #59610 on GoodFellas Big Board Catalyst and Chart Plays

[xtremezz]

Sarepta's eteplirsen accelerated approval could be denied, TheStreet.com reports

Stock been in the spotlight again lately.

According to TheStreet.com, accelerated approval for Sarepta's (SRPT) eteplirsen, a novel experimental drug for Duchenne Muscular Dystrophy, will be denied by the FDA. Instead, TheStreet says it is more likely Sarepta will be required to perform a larger pivotal study prior to submitting the drug for FDA review.